Reduction of gastrointestinal symptoms in Parkinson's disease afteraswitch from oral therapy to rotigotine transdermal patch: Anon-interventional prospective multicenter trial

Parkinsonism and Related Disorders

Volumn 21, Issue 3, 2015, Pages 199-204

  Woitalla, Dirk ^a   Kassubek, Jan ^b   Timmermann, Lars ^c   Lauterbach, Thomas ^d   Berkels, Reinhard ^d   Grieger, Frank ^d   Müller, Thomas ^e  

^a ST JOSEF HOSPITAL   (Germany)

^b UNIVERSITY OF ULM   (Germany)

^c UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^d UCB PHARMA   (Belgium)

^e St Joseph Hospital   (Germany)

Author keywords

Dopamine agonist; Gastrointestinal; Non motor; Parkinson's disease; Rotigotine

Indexed keywords

AMANTADINE; ANTIPARKINSON AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; MONOAMINE OXIDASE B INHIBITOR; ROTIGOTINE; TETRALIN DERIVATIVE; THIOPHENE DERIVATIVE;

ABDOMINAL PAIN; AGED; ARTICLE; BLOATING; CLINICAL TRIAL; CONTACT DERMATITIS; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPHAGIA; ERYTHEMA; FEMALE; GASTROINTESTINAL SYMPTOM; HEARTBURN; HEMATOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); NAUSEA; OBSERVATIONAL STUDY; PARKINSON DISEASE; PATIENT SATISFACTION; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PRURITUS; SKIN IRRITATION; SLEEP DISORDER; SPINE FRACTURE; TRANSDERMAL PATCH; TREATMENT OUTCOME; VOMITING; COMPLICATION; FOLLOW UP; GASTROINTESTINAL DISEASES; MIDDLE AGED; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PAIN MEASUREMENT; VERY ELDERLY;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANTIPARKINSON AGENTS; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL DISEASES; HUMANS; MALE; MIDDLE AGED; PAIN MEASUREMENT; PARKINSON DISEASE; PATIENT SATISFACTION; TETRAHYDRONAPHTHALENES; THIOPHENES; TRANSDERMAL PATCH;

EID: 84923216956     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2014.11.024     Document Type: Article

References (30)

1. Pfeiffer R.F. Gastrointestinal dysfunction in Parkinson's disease. Park Relat Disord 2011, 17:10-15.
2. Heetun Z.S., Quigley E.M. Gastroparesis and Parkinson's disease: a systematic review. Park Relat Disord 2012, 18:433-440.
3. Braak H., Del Tredici K. Neuroanatomy and pathology of sporadic Parkinson's disease 2009, Springer Verlag, Berlin.
4. Barone P., Antonini A., Colosimo C., Marconi R., Morgante L., Avarello T.P., et al. The PRIAMO study: a multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease. Mov Disord 2009, 24:1641-1649.
5. Kupsky W.J., Grimes M.M., Sweeting J., Bertsch R., Cote L.J. Parkinson's disease and megacolon: concentric hyaline inclusions (Lewy bodies) in enteric ganglion cells. Neurology 1987, 37:1253-1255.
6. Singaram C., Ashraf W., Gaumnitz E.A., Torbey C., Sengupta A., Pfeiffer R., et al. Dopaminergic defect of enteric nervous system in Parkinson's disease patients with chronic constipation. Lancet 1995, 346:861-864.
7. Wakabayashi K., Takahashi H., Ohama E., Ikuta F. Parkinson's disease: an immunohistochemical study of Lewy body-containing neurons in the enteric nervous system. Acta Neuropathol 1990, 79:581-583.
8. Braak H., de Vos R.A., Bohl J., Del Tredici K. Gastric alpha-synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology. Neurosci Lett 2006, 396:67-72.
9. Tanaka Y., Kato T., Nishida H., Yamada M., Koumura A., Sakurai T., et al. Is there a delayed gastric emptying of patients with early-stage, untreated Parkinson's disease? An analysis using the 13C-acetate breath test. JNeurol 2011, 258:421-426.
10. Del Tredici K., Braak H. Lewy pathology and neurodegeneration in premotor Parkinson's disease. Mov Disord 2012, 27:597-607.
11. Savica R., Carlin J.M., Grossardt B.R., Bower J.H., Ahlskog J.E., Maraganore D.M., et al. Medical records documentation of constipation preceding Parkinson disease: a case-control study. Neurology 2009, 73:1752-1758.
12. Abbott R.D., Ross G.W., Petrovitch H., Tanner C.M., Davis D.G., Masaki K.H., et al. Bowel movement frequency in late-life and incidental Lewy bodies. Mov Disord 2007, 22:1581-1586.
13. Li Z.S., Schmauss C., Cuenca A., Ratcliffe E., Gershon M.D. Physiological modulation of intestinal motility by enteric dopaminergic neurons and the D2 receptor: analysis of dopamine receptor expression, location, development, and function in wild-type and knock-out mice. JNeurosci 2006, 26:2798-2807.
14. Hardoff R., Sula M., Tamir A., Soil A., Front A., Badarna S., et al. Gastric emptying time and gastric motility in patients with Parkinson's disease. Mov Disord 2001, 16:1041-1047.
15. Djaldetti R., Baron J., Ziv I., Melamed E. Gastric emptying in Parkinson's disease: patients with and without response fluctuations. Neurology 1996, 46:1051-1054.
16. Desai J.K., Goyal R.K., Parmar N.S. Characterization of dopamine receptor subtypes involved in experimentally induced gastric and duodenal ulcers in rats. JPharm Pharmacol 1999, 51:187-192.
17. Hirst B.H., Reed J.D., Gomez-Pan A., Labib L.A. Bromocriptine potentiation of gastric acid secretion in cats. Clin Endocrinol (Oxf) 1976, 5:723-729.
18. Scheller D., Ullmer C., Berkels R., Gwarek M., Lubbert H. The invitro receptor profile of rotigotine: a new agent for the treatment of Parkinson's disease. Naunyn Schmiedebergs Arch Pharmacol 2009, 379:73-86.
19. Elshoff J.P., Braun M., Andreas J.O., Middle M., Cawello W. Steady-state plasma concentration profile of transdermal rotigotine: an integrated analysis of three, open-label, randomized, phase I multiple dose studies. Clin Ther 2012, 34:966-978.
20. Giladi N., Boroojerdi B., Korczyn A.D., Burn D.J., Clarke C.E., Schapira A.H. Rotigotine transdermal patch in early Parkinson's disease: a randomized, double-blind, controlled study versus placebo and ropinirole. Mov Disord 2007, 22:2398-2404.
21. Watts R.L., Jankovic J., Waters C., Rajput A., Boroojerdi B., Rao J. Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease. Neurology 2007, 68:272-276.
22. LeWitt P.A., Lyons K.E., Pahwa R. Advanced Parkinson disease treated with rotigotine transdermal system: PREFER Study. Neurology 2007, 68:1262-1267.
23. Poewe W.H., Rascol O., Quinn N., Tolosa E., Oertel W.H., Martignoni E., et al. Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial. Lancet Neurol 2007, 6:513-520.
24. Trenkwalder C., Kies B., Rudzinska M., Fine J., Nikl J., Honczarenko K., et al. Rotigotine effects on early morning motor function and sleep in Parkinson's disease: a double-blind, randomized, placebo-controlled study (RECOVER). Mov Disord 2011, 26:90-99.
25. ® (Rotigotine transdermal patch). Summary of product characteristics 19 August, 2013, UCB Manufacturing Ireland Ltd, Ireland.
26. Drossman D.A. The functional gastrointestinal disorders and the Rome III process. Gastroenterology 2006, 130:1377-1390.
27. LeWitt P.A., Boroojerdi B., MacMahon D., Patton J., Jankovic J. Overnight switch from oral dopaminergic agonists to transdermal rotigotine patch in subjects with Parkinson disease. Clin Neuropharmacol 2007, 30:256-265.
28. Kim H.J., Jeon B.S., Lee W.Y., Lee M.C., Kim J.W., Kim J.M., et al. Overnight switch from ropinirole to transdermal rotigotine patch in patients with Parkinson disease. BMC Neurol 2011, 11:100.
29. Goetze O., Nikodem A.B., Wiezcorek J., Banasch M., Przuntek H., Mueller T., et al. Predictors of gastric emptying in Parkinson's disease. Neurogastroenterol Motil 2006, 18:369-375.
30. Woitalla D., Goetze O. Treatment approaches of gastrointestinal dysfunction in Parkinson's disease, therapeutical options and future perspectives. JNeurol Sci 2011, 310:152-158.